Cargando…

Effect of Telmisartan on Histological Activity and Fibrosis of Non-alcoholic Steatohepatitis: A 1-Year Randomized Control Trial

BACKGROUND/AIM: Telmisartan can attenuate two hit pathogenesis of non-alcoholic steatohepatitis (NASH). This study aimed to observe the effect of Telmisartan on non-alcoholic fatty liver disease (NAFLD) activity score (NAS) and fibrosis score in NASH patients. PATIENTS AND METHODS: A total of 50 NAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alam, Shahinul, Kabir, Jahangir, Mustafa, Golam, Gupta, UtpalDas, Hasan, SKMNazmul, Alam, AKMKhorshed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763532/ https://www.ncbi.nlm.nih.gov/pubmed/26831610 http://dx.doi.org/10.4103/1319-3767.173762

Ejemplares similares

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
por: Alam, Shahinul, et al.
Publicado: (2018)

Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient
por: Alam, Shahinul, et al.
Publicado: (2019)

Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial
por: Alam, Shahinul, et al.
Publicado: (2020)

Biochemical Scoring System for diagnosing Nonalcoholic Steatohepatitis
por: Noor-E-Alam, Mohammad, et al.
Publicado: (2016)

Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan
por: Park, Jung Gyu, et al.
Publicado: (2019)

Comparative Study on Presentation of Biliary Ascariasis with Dead and Living Worms
por: Alam, Shahinul, et al.
Publicado: (2010)

Prevalence and risk factors of non‐alcoholic fatty liver disease in Bangladesh
por: Alam, Shahinul, et al.
Publicado: (2018)

Natural Course of Fulminant Hepatic Failure: The Scenario in Bangladesh and the Differences from the West
por: Alam, Shahinul, et al.
Publicado: (2009)

Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma
por: Yu, Junjie, et al.
Publicado: (2023)

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
por: Harrison, Stephen A., et al.
Publicado: (2019)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation
por: Kuwashiro, Shinya, et al.
Publicado: (2011)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Estimating the cost of illness of non‐alcoholic fatty liver disease in Bangladesh
por: Alam, Shahinul, et al.
Publicado: (2023)

P2X7 Receptor in Alcoholic Steatohepatitis and Alcoholic Liver Fibrosis
por: Xia, Guo-Qing, et al.
Publicado: (2022)

The Correlation between Serum Zinc Level and Liver Histology in Non-Alcoholic Steatohepatitis
por: Kosari, Farid, et al.
Publicado: (2019)

Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
por: Phisalprapa, Pochamana, et al.
Publicado: (2021)

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children
por: Kordy, Kattayoun, et al.
Publicado: (2021)

Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats
por: Murad, Hussam, et al.
Publicado: (2020)

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs
por: Golder, Matthew R., et al.
Publicado: (2018)

Variant of Ascitic Fluid Bacterial Infections in Patients of Liver Cirrhosis
por: Alam Sarker, Jahangir, et al.
Publicado: (2015)

Telmisartan induced urticarial vasculitis
por: Mahajan, Vikram K., et al.
Publicado: (2015)

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
por: Matsumoto, Masahiko, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
por: Verlinden, Wim, et al.
Publicado: (2020)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Integrating stress signals—XBP1 as a novel mediator of intercellular crosstalk in non-alcoholic steatohepatitis
por: Yu, Junjie, et al.
Publicado: (2022)

Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011)

Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis
por: Billeter, Adrian T., et al.
Publicado: (2022)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats
por: Liu, Qian, et al.
Publicado: (2022)

Characterization of High-Fat, Diet-Induced, Non-alcoholic Steatohepatitis with Fibrosis in Rats
por: Xu, Zheng-Jie, et al.
Publicado: (2009)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis
por: Li, Yadi, et al.
Publicado: (2021)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis
por: Yu, Amy, et al.
Publicado: (2022)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans
por: Itoh, Michiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_oafkq4ql7usoktkgkaej4h7q3c